FierceBiotechOriginal article
{"a":[{"_":"MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter ","$":{"href":"/biotech/maplight-turns-preclinical-tap-channel-resources-phase-3-ready-schizophrenia-drug","hreflang":"en"}}]}
Phase 3MixedNegative
AI Analysis
Summary
MapLight Therapeutics is consolidating its portfolio around a phase 3-ready schizophrenia drug despite mixed recent results, dimming its preclinical programs to focus resources on the lead asset.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Mixed results for experimental schizophrenia treatment reported last month
Importance:5/10
Sentiment:
-0.30
schizophreniaphase 3mixed resultsresource allocationpreclinical programs
Read the original article
Published by FierceBiotech on August 14, 2026 4:41 AM